HEBP2

Across TCGA pan-cancer cohorts, HEBP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HEBP2 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HEBP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HEBP2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where HEBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.375	1.000	.003	44	view →
CCRCC	OS	Median	II,III,IV	1.000	0.822	.006	20	view →
PDAC	DFS	Quartile	All	0.880	0.688	.012	9	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
UCEC	DFS	Tertile	All	0.957	0.812	.021	6	view →
HNSC	OS	Quartile	All	0.938	1.000	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HEBP2–LUAD (DFS)

Open the LUAD breakdown →